- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 5/02 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link
Patent holdings for IPC class C07K 5/02
Total number of patents in this class: 759
10-year publication summary
|
59
|
77
|
67
|
73
|
51
|
37
|
52
|
53
|
32
|
10
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| SeaGen Inc | 546 |
19 |
| Janssen Pharmaceutica N.V. | 3226 |
15 |
| Revolution Medicines, Inc. | 316 |
14 |
| F. Hoffmann-La Roche AG | 7841 |
13 |
| Hoffmann-La Roche Inc. | 3718 |
13 |
| Endocyte, Inc. | 114 |
12 |
| ImmunoGen, Inc. | 382 |
12 |
| Kyowa Hakko Bio Co., Ltd. | 291 |
11 |
| Novartis AG | 10341 |
9 |
| The Regents of the University of California | 20587 |
8 |
| Siemens Medical Solutions USA, Inc. | 1470 |
8 |
| President and Fellows of Harvard College | 6055 |
8 |
| Pfizer Inc. | 3370 |
7 |
| Ajinomoto Co., Inc. | 2277 |
7 |
| Cornell University | 3396 |
7 |
| Dana-Farber Cancer Institute, Inc. | 2654 |
7 |
| Zymeworks Inc. | 253 |
7 |
| Merck Patent GmbH | 5669 |
6 |
| Ambrx, Inc. | 170 |
6 |
| Karus Therapeutics Limited | 27 |
6 |
| Other owners | 564 |